WO2004000094A3 - Predictive markers in cancer therapy - Google Patents
Predictive markers in cancer therapy Download PDFInfo
- Publication number
- WO2004000094A3 WO2004000094A3 PCT/US2003/012739 US0312739W WO2004000094A3 WO 2004000094 A3 WO2004000094 A3 WO 2004000094A3 US 0312739 W US0312739 W US 0312739W WO 2004000094 A3 WO2004000094 A3 WO 2004000094A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer therapy
- predictive markers
- markers
- egf
- responding
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03724213A EP1810034A4 (en) | 2002-06-19 | 2003-04-24 | Predictive markers in cancer therapy |
AU2003235470A AU2003235470A1 (en) | 2002-06-19 | 2003-04-24 | Predictive markers in cancer therapy |
US10/529,922 US20060094068A1 (en) | 2002-06-19 | 2003-04-24 | Predictive markers in cancer therapy |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38979502P | 2002-06-19 | 2002-06-19 | |
US60/389,795 | 2002-06-19 | ||
US43281102P | 2002-12-11 | 2002-12-11 | |
US43294302P | 2002-12-11 | 2002-12-11 | |
US60/432,943 | 2002-12-11 | ||
US60/432,811 | 2002-12-11 | ||
US45197803P | 2003-03-05 | 2003-03-05 | |
US60/451,978 | 2003-03-05 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2004000094A2 WO2004000094A2 (en) | 2003-12-31 |
WO2004000094A8 WO2004000094A8 (en) | 2007-04-12 |
WO2004000094A3 true WO2004000094A3 (en) | 2007-06-14 |
Family
ID=30003983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/012739 WO2004000094A2 (en) | 2002-06-19 | 2003-04-24 | Predictive markers in cancer therapy |
Country Status (4)
Country | Link |
---|---|
US (1) | US20060094068A1 (en) |
EP (1) | EP1810034A4 (en) |
AU (1) | AU2003235470A1 (en) |
WO (1) | WO2004000094A2 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3115470B1 (en) | 2002-03-13 | 2018-07-18 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
US20040248151A1 (en) * | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
US20090111127A1 (en) * | 2002-05-21 | 2009-04-30 | Monogram Biosciences Inc. | Surface Receptor Complexes as Biomarkers |
JP4606879B2 (en) | 2002-11-15 | 2011-01-05 | ジェノミック ヘルス, インコーポレイテッド | Gene expression profiling of EGFR positive cancer |
WO2005011607A2 (en) * | 2003-08-01 | 2005-02-10 | Smithkline Beecham Corporation | Treatment of cancers expressing p95 erbb2 |
EP1664716A4 (en) * | 2003-08-15 | 2008-08-13 | Smithkline Beecham Corp | Biomarkers in cancer |
WO2005094332A2 (en) * | 2004-03-26 | 2005-10-13 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer |
AU2005251722B2 (en) * | 2004-06-03 | 2009-11-12 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
WO2005121380A1 (en) * | 2004-06-04 | 2005-12-22 | Smithkline Beecham Corporation | Predictive biomarkers in cancer therapy |
WO2006045991A1 (en) * | 2004-10-25 | 2006-05-04 | Astrazeneca Ab | Method to predict whether a tumor will react to a chemotherapeutic treatment |
US20060127935A1 (en) * | 2004-12-15 | 2006-06-15 | Nsabp Foundation, Inc. | Identification and use of prognostic and predictive markers in cancer treatment |
US7449184B2 (en) | 2005-01-21 | 2008-11-11 | Genentech, Inc. | Fixed dosing of HER antibodies |
PT1850874E (en) | 2005-02-23 | 2013-12-02 | Genentech Inc | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
TW200716204A (en) | 2005-04-19 | 2007-05-01 | Smithkline Beecham Cork Ltd | Pharmaceutical composition |
US20060246536A1 (en) * | 2005-04-29 | 2006-11-02 | Margaret Hardy | Xenograft tissue control for histology |
AU2007248424B2 (en) | 2006-05-05 | 2013-04-18 | Historx, Inc. | Immunohistochemical methods for determining signal transduction activity in tumors |
US20080050757A1 (en) * | 2006-08-23 | 2008-02-28 | Sarah Bacus | Rapid method for detecting mutated genes |
DK2081950T3 (en) * | 2006-09-21 | 2013-06-03 | Nuclea Biomarkers Llc | Expression profiles associated with irinotecan treatment |
CA2675370A1 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms as sex-specific predictors in cancer therapy |
WO2008088861A2 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms predictive for dual tki therapy |
PE20090681A1 (en) | 2007-03-02 | 2009-06-10 | Genentech Inc | PREDICTION OF RESPONSE TO A HER INHIBITOR |
CA2690334C (en) | 2007-06-08 | 2017-02-14 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
BRPI0812682A2 (en) | 2008-06-16 | 2010-06-22 | Genentech Inc | metastatic breast cancer treatment |
WO2010091198A1 (en) | 2009-02-06 | 2010-08-12 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
US8568968B2 (en) * | 2009-04-13 | 2013-10-29 | University Of Southern California | EGFR polymorphisms predict gender-related treatment |
JP5705836B2 (en) | 2009-05-29 | 2015-04-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Modulators for HER2 signaling in gastric cancer patients expressing HER2 |
EP2438443A4 (en) * | 2009-06-02 | 2012-07-25 | Targeted Molecular Diagnostics Llc | Methods for the detection and quantitation of the p95 component of her2/neu (erbb2) |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
US8809026B2 (en) | 2011-12-27 | 2014-08-19 | Commonwealth Scientific And Industrial Research Organisation | Processes for producing lipids |
BR112015012644A2 (en) | 2012-11-30 | 2017-12-19 | Hoffmann La Roche | method for determining a cancer patient's need, cancer treatment method, pharmaceutical composition, use of a nucleic acid or antibody and kit; |
CN107091930B (en) * | 2017-03-07 | 2020-09-15 | 杭州百凌生物科技有限公司 | Method for rapidly predicting and improving sensitivity of non-small cell lung cancer cells to epidermal growth factor receptor inhibitor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050004008A1 (en) * | 2002-03-01 | 2005-01-06 | Frackelton A. Raymond | SHC proteins as therapeutic targets in proliferative diseases |
US20060040338A1 (en) * | 2004-08-18 | 2006-02-23 | Odyssey Thera, Inc. | Pharmacological profiling of drugs with cell-based assays |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001580A (en) * | 1995-03-28 | 1999-12-14 | Takeda Chemical Industries, Inc. | Method for assaying ERK2 map kinase |
US7541141B2 (en) * | 1997-02-27 | 2009-06-02 | Wisconsin Alumni Research Foundation | Method of using estrogen-related receptor alpha (ERRα) status to determine prognosis, treatment strategy and predisposition to breast cancer, and method of using ERRα as a therapeutic target for the treatment of breast cancer |
US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
US20030124130A1 (en) * | 2002-01-02 | 2003-07-03 | Brown Robert E. | Proteomic analysis of tumors for development of consultative report of therapeutic options |
-
2003
- 2003-04-24 EP EP03724213A patent/EP1810034A4/en not_active Withdrawn
- 2003-04-24 AU AU2003235470A patent/AU2003235470A1/en not_active Abandoned
- 2003-04-24 WO PCT/US2003/012739 patent/WO2004000094A2/en not_active Application Discontinuation
- 2003-04-24 US US10/529,922 patent/US20060094068A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050004008A1 (en) * | 2002-03-01 | 2005-01-06 | Frackelton A. Raymond | SHC proteins as therapeutic targets in proliferative diseases |
US20060040338A1 (en) * | 2004-08-18 | 2006-02-23 | Odyssey Thera, Inc. | Pharmacological profiling of drugs with cell-based assays |
Non-Patent Citations (3)
Title |
---|
NG S.S.W. ET AL.: "Effects of the Epidermal Growth Factor Receptor Inhibitor OSI-774, Tarceva, on Downstream Signaling Pathways and Apoptosis in Human Pancreatic Adenocarcinoma", MOLECULAR CANCER THERAPEUTICS, vol. 1, August 2002 (2002-08-01), pages 777 - 783, XP009056210 * |
See also references of EP1810034A4 * |
SUAREZ C. ET AL.: "Angiotensin II phosphorylation of extracellular signal-regulated kinases in rat anterior pituitary cells", AMERICAN JOURNAL OF PHYSIOLOGICAL ENDOCRINOLOGICAL METABOLISM, vol. 285, May 2003 (2003-05-01), pages E645 - E653, XP003013757 * |
Also Published As
Publication number | Publication date |
---|---|
EP1810034A2 (en) | 2007-07-25 |
US20060094068A1 (en) | 2006-05-04 |
WO2004000094A2 (en) | 2003-12-31 |
EP1810034A4 (en) | 2008-06-25 |
AU2003235470A1 (en) | 2004-01-06 |
WO2004000094A8 (en) | 2007-04-12 |
AU2003235470A8 (en) | 2004-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004000094A3 (en) | Predictive markers in cancer therapy | |
WO2004113571A3 (en) | Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis | |
WO2004000102A3 (en) | Method for predicting response to epidermal growth factor receptor-directed therapy | |
WO2004071572A3 (en) | Gene expression markers for response to egfr inhibitor drugs | |
DK0961780T3 (en) | Protein markers for lung cancer and its use | |
WO2005017493A3 (en) | Biomarkers in cancer | |
CY1113247T1 (en) | NUCLEAR ACIDS WITH THE TITLE 273P4B7 AND USE IN CANCER TEST | |
WO2004053066A3 (en) | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy | |
WO2003004989A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | |
WO2001025272A3 (en) | Compositions and methods for therapy and diagnosis of prostate cancer | |
WO2004050707A3 (en) | Tumor-specific recognition molecules | |
WO2004106495A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | |
BR0109062A (en) | Aryl fructose-1,6-bisphosphatase inhibitors | |
WO2005092073A3 (en) | Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation | |
WO2005113831A3 (en) | Biomarkers for multiple sclerosis and methods of use thereof | |
AU2003226676A1 (en) | Methods and compositions for the identification, assessment, and therapy of small cell lung cancer | |
AU2003293141A1 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
WO2004009024A3 (en) | Modulation of protein kinase c-iota expression | |
WO2005014846A3 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
DE60044350D1 (en) | PROSTATE SPECIFIC GEN PCGEM1 AND METHODS OF USE FOR THE RECOGNITION, TREATMENT AND PREVENTION OF PROSTATE CANCER | |
WO2001042792A3 (en) | Diagnosis of cervical cancer using marker proteins | |
WO2004027418A3 (en) | The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity | |
WO2004013313A3 (en) | Antisense nucleic acids | |
WO2003045321A3 (en) | MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE | |
WO2002093127A3 (en) | Methods and reagents for identifying insulin response modulators and therapeutic uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2006094068 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10529922 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003724213 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10529922 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003724213 Country of ref document: EP |